Navigation Links
GeneNews to exhibit ColonSentry(TM) at Family Medicine Forum 2008
Date:11/26/2008

TORONTO, Nov. 26 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it will be exhibiting at the Family Medicine Forum 2008 being held at the Sheraton Centre in Toronto from November 27th to November 29th, 2008. GeneNews' exhibit, at booth # 400, will feature the Company's lead product, ColonSentry(TM), the world's first blood-based test to determine a person's current risk for colorectal cancer.

"This event, which attracts more than 1500 family physicians and healthcare professionals, is the premier family medicine conference in Canada and the ideal audience to increase the awareness of ColonSentry(TM) in Canada," said Gailina Liew, Chief Operating Officer of GeneNews. "Building on the expanded roll out of ColonSentry(TM) at additional locations in the Greater Toronto Area last week, our exhibition at the Family Medicine Forum will further support our Canadian commercialization strategy as we plan to offer ColonSentry(TM) in other regions of Canada throughout 2009."

The Family Medicine Forum combines the Annual Scientific Assemblies of the College of Family Physicians of Canada (CFPC), the Ontario College of Family Physicians (OCFP), and the Annual Workshops of the CFPC's Sections of Teachers and Researchers. For additional information please visit ww.fmf.cfpc.ca.

    About GeneNews
    --------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
2. GeneNews appoints Canadian Colorectal Cancer Advisory Board
3. GeneNews restructures operations
4. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
5. GeneNews Announces Second Quarter Results
6. GeneNews launches worlds first blood test for colorectal cancer screening
7. GeneNews announces management changes to support commercialization of ColonSentry(TM)
8. Genenews adds two members to its Board of Directors
9. GeneNews Announces First Quarter Results
10. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
11. GeneNews announces 2007 year end results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):